Telix Pharmaceuticals: The ITM Deal Could Strengthen The Long-Term Buy Case (NASDAQ:TLX)
· seekingalpha.com
Telix Pharmaceuticals maintains a Buy rating, driven by robust 3Q26 performance and the strategic ITM acquisition. Read more on TLX stock here.
Since my previous coverage on Telix Pharmaceuticals Limited ( TLX ), the stock has had a few ups and downs, but for the most part, it’s trading around similar...